Immunotherapy by Naing, Aung

Immunotherapy (Hardcover) (ISBN-13: 9783030793074)

Vendor: Aung Naing
Product type: Books
Format: Hardcover
$249.99
$249.99
$249.99
Subtotal: $249.99
Immunotherapy by Naing, Aung

Immunotherapy

$249.99
Immunotherapy by Naing, Aung

Immunotherapy

$249.99
Format: Hardcover
Description
Description
x

Table of contents


1. Immune System in Action

2. Resistance to Immunotherapy: Mechanisms and Means for Overcoming

3. Immunotherapy for Melanoma


4. Immunotherapy in Lung Cancer: Are the promises of long-term benefit finally met?


5. Landscape of Immunotherapy in Genitourinary Malignancies


6. Immuno-oncology for Gynecologic Malignancies


7. Immunotherapy for Neuro-oncology


8. Immunotherapy in Gastrointestinal Malignancies


9. An update on immune based therapies in acute myeloid leukemia: 2021 and beyond!


10. CAR T-cells


11. Skin Reactions to Immune Checkpoint Inhibitors

12. Immunotherapy Mediated luminal Gastrointestinal toxicities


13. Hepatobiliary and Pancreatic Adverse Events


14. Pulmonary toxicities of immunotherapy


15. Immune checkpoint inhibitors (ICIs) related cardiotoxicity


16. Renal Toxicity


17. Immune-Related Oral, Otologic and Ocular Adverse Events


18. Neurologic Toxicities of Immunotherapy


19. Cancer Imaging in Immunotherapy




Author: Aung Naing
ISBN-10: 3030793079
ISBN-13: 9783030793074
Publisher: Springer
Language: English
Published: 12/21/2021
Pages: 447
Format: Hardcover
Weight: 2.21lbs
Size: 10.00h x 7.00w x 1.00d
By Aung Naing
By Aung Naing
x

Dr. Aung Naing is a Professor in the Department of Investigational Cancer Therapeutics at MD Anderson Cancer Center and is also a Principal Investigator on immunotherapy-based clinical trials. Focusing on clinical translation of basic immunobiology, Dr. Naing's research interests are (1) identifying immunologic biomarkers of response to immunotherapy, (2) predicting primary and secondary resistance to immunotherapy, (3) developing immunotherapeutic strategies to overcome resistance, and (4) identifying predictive markers for immune-related adverse events (irAE) associated with immunotherapies.

Dr. Joud Hajjar is an Assistant Professor of Allergy and Immunology and serves as the service chief of adult allergy and immunology at Texas Children's Hospital. She is a member of the Basic and Clinical Immunology Interest group at the American Academy of Allergy Asthma and Immunology, and the Women in Clinical Immunology Committee at the Clinical Immunology Society. Dr. Hajjar's research interests are in inborn errors of immunity, microbiome in the immunocompromised host, and cancer immunotherapy.

Recently Viewed Products